Abstract
Get full access to this article
View all access options for this article.
References
1.
Nanus
DM
Milowsky
MI
. Genitourinary cancers . In:
Moore
A
Appelbaum
FR
Loprinzi
CL
Ruggerio
JT
. ASCO—SEP Medical Oncology Self—Evaluation Program . 2nd ed. Alexandria,VA : ASCO ; 2010 :263 -264 .
2.
Damber
J-K
Anus
G
. Prostate cancer . Lancet . 2008 ;371 : 1710 -1721 .
3.
Fizazi
KF
Scher
HI
Molina
A
. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study . Lancet Oncol . 2012 ;13 :983 -992 .
4.
Sonpavde
G
. Abiraterone acetate for metastatic prostate cancer . Lancet Oncol . 2012 ;13 :958 -959 .
5.
Scher
HI
Fizazi
K
Saad
F
. Increased survival with enzalutamide in prostate cancer after chemotherapy . N Engl J Med . 2012 ;367 :1187 -1197 .
6.
Higano
CS
. New treatment options for patients with metastatic castration-resistant prostate cancer . Cancer Treat Rev . 2012 ; 38 :340 -345 .